The analysis demonstrated that JAKI, as well as the phosphodiesterase-4 Inhibitor (PDE4 Inhibitor), apremilast, showed notable efficacy in the treatment of vitiligo across various age groups. The gene discussed is PDE4A; the disease is vitiligo.